Insider Buying: Elanco Animal Health (NYSE:ELAN) CFO Purchases 6,950 Shares of Stock

Elanco Animal Health Incorporated (NYSE:ELAN) CFO Robert Vanhimbergen acquired 6,950 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The shares were acquired at an average cost of $21.64 per share, with a total value of $150,398.00. Following the purchase, the chief financial officer directly owned 124,233 shares of the company’s stock, valued at $2,688,402.12. This trade represents a 5.93% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Elanco Animal Health Price Performance

ELAN traded up $0.43 during trading on Monday, reaching $21.72. The stock had a trading volume of 5,970,920 shares, compared to its average volume of 5,860,102. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40. The stock has a market cap of $10.79 billion, a PE ratio of 361.98, a PEG ratio of 2.89 and a beta of 1.86. The business has a 50-day moving average of $21.73 and a 200-day moving average of $18.10. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $23.70.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the previous year, the firm posted $0.13 earnings per share. The firm’s revenue for the quarter was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. As a group, equities research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ELAN. Stifel Nicolaus upped their target price on shares of Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Wall Street Zen raised Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 15th. UBS Group lifted their target price on shares of Elanco Animal Health from $25.00 to $27.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Argus upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Wednesday, November 19th. Finally, KeyCorp reiterated an “overweight” rating on shares of Elanco Animal Health in a research report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.78.

Hedge Funds Weigh In On Elanco Animal Health

A number of institutional investors and hedge funds have recently made changes to their positions in ELAN. SJS Investment Consulting Inc. increased its position in shares of Elanco Animal Health by 2,563.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after purchasing an additional 1,333 shares during the last quarter. Huntington National Bank lifted its holdings in Elanco Animal Health by 136.7% during the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after buying an additional 1,087 shares in the last quarter. Whittier Trust Co. of Nevada Inc. boosted its holdings in shares of Elanco Animal Health by 80.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after purchasing an additional 900 shares during the period. Farther Finance Advisors LLC grew its position in shares of Elanco Animal Health by 79.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after buying an additional 951 shares in the last quarter. Finally, Fifth Third Bancorp grew its holdings in Elanco Animal Health by 3,018.3% during the 3rd quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock worth $58,000 after acquiring an additional 2,807 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.